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The class I antigens encoded within the MHC of the mouse are cell surface
glycoproteins that play an essential role in immune recognition and regulation.
CTL exhibit an absolute requirement for associated recognition of foreign
antigens in the context of self MHC components (1). In addition, CTL can
recognize non-self MHC molecules. This specific recognition ofnon-self MHC,
known as allorecognition, is the cellular basis ofthe well known phenomenon of
allograft rejection.
Class I antigens also appear to be involvedin the immune elimination ofcertain
tumors (2, 3). Many tumors are highly immunogenic and are rejected when
transplanted into normal, histocompatible mice (2-6). Theability ofsuch tumors
to arise in the autochthonous host might therefore represent the consequence of
a compromised immune system that cannot limit neoplastic progression. In fact,
many carcinogenic treatments, such as UV irradiation, are also immunosuppres-
sive (5), and this might contribute to the outgrowth of otherwise immunogenic
neoplastic cells. Consequently, ^-75% ofthe tumors that arise in UV-treated mice
are rejected in normal syngeneic recipients but progress in UV-irradiated animals
(5, 6). Interestingly, the immune suppression associated with UV irradiation
appears to be specific for tumors arising in UV-irradiated hosts (7) and can be
mediated by specific Ts (8). To understand the complex biology ofthese tumors,
it is necessary to identify and characterize the molecules responsible both for
their immunogenicity and for their ability to escape the immune system in UV-
treated animals.
One UV-induced tumor that has been extensively studied is the C3H fibrosar-
cotna, 1591 (5). It has recently been shown (9, 10) that 1591 expresses at least
three novel class I antigens not normally found on C3H tissue. These novel
antigens have been identified by mAbs derived from normal C3H mice immu-
nized with the tumor and are also recognized by allospecific anti-H-2 mAbs (9,
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10). Certain tumor variants lacking the novel antigens can grow progressively in
immunocompetent hosts, suggesting that these molecules may play an important
role in the biology of this tumor (11) . The isolation of the genes encoding the
novel antigens, termed A 149, A 166, and A216, has been previously described
(12). Since these genes account for several of the polymorphic restriction frag-
ments observed in the class I genes of 1591 when compared with C3H by
genomic Southern blot analysis, we have previously proposed (12) that these
genes were generated by recombination events among the endogenous class I
genes of C3H . To determine the origin of these novel genes and the role of
their products in the neoplastic process, it is necessary to characterize their
structure and examine the extent to which each molecule can be recognized by
the immune system.
In this report, we present the complete DNA sequence of these three novel
class I genes, and describe in detail the recognition of their products by alloreac-
tive and tumor-specific CTL. We find that these genes are highly homologous
to those of previously characterized class I antigens, such as H-2Kk (13) and H-
2L`' (14), and that the structural conservation seen among these gene products
is reflected in their functional homology as well . Since the class I diversification
events by which these novel tumor genes were generated probably parallel events
that occur in the germline, the identification and analysis of the parental C3H
genes from which they were derived might be relevant to the study of class I
evolution. Furthermore, the discrete pattern of structural and functional ho-
mology seen among A 149, A 166, and H-2L' suggests that functional analysis of
these novel H-2L products should provide significant insight not only into the
role that these molecules played in the progression of the 1591 tumor, but also
into the structural basis of T cell recognition .
Materials and Methods
Materials.
￿
Restriction endonucleases were obtained from New England Biolabs, Bev-
erly, MA. Escherichia coli DNA polymerase Klenow fragment was obtained from Boehrin-
ger Mannheim Biochemicals, Indianapolis, IN. E. coli strain JM103, phage MI3mpl8,
and mp19 were the gift of Dr. Chuck Staben (Department of Biochemistry, University of
California, Berkeley). Oligonucleotide primers homologous to class I sequence were
synthesized by Lynn Williams at the University of Southern California Medical Center,
and by Bruce Malcolm at the Department of Biochemistry, University of California,
Berkeley.
Cell Lines and Animals.
￿
The C3H origin of the 1591 tumor has been previously
documented (9, 10, 12). The 1591 tumor and the 28- tumor variant (9) were the kind
gift of Dr. Hans Schreiber (Department of Pathology, University of Chicago). L cell
transfectants were generated previously (12). Mice were bred and maintained in the
colony at the University of Texas Health Science Center, Dallas.
DNA Sequence Analysis.
￿
The genes were sequenced in parallel by the dideoxy chain
termination method (15) using a set of 40 synthetic oligonucleotide primers complemen-
tary to class I sequences. We chose primers that hybridize at 200-250 by intervals in both
orientations, according to the DNA sequence of the H-2Dd gene (16). Up to 350 by were
read per sequencing reaction on 5% urea/7% polyacrylamide gels.
Generation of Cytotoxic T Lymphocytes.
￿
To generate CTL activity against the 1591
tumor or L cells transfected with tumor-derived class I genes, (C3H x dm2)F, animals
were inoculated intraperitoneally with 107 tumor or transfected L cells. ^-3 wk later,
spleens were removed from the primed animals and these cells were cultured in vitro with
either x-irradiated (3,000 rad) tumor cells, L cells transfected with the tumor genes, or796
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TABLE I
Summaryofthe Class I Specificities Displayed on the UV Tumor 1591
Results
Summary ofthe class I specificities displayed on theUV tumor, 1591 . Specificities
and tentative domain assignments of antibodies 34-1-2, 34-4-20, 30-5-7, and 28-
14-8 were previously determined (19-22) . CP28 and CP3F4 are 1591-specific
mAbs (9), which have been mapped to the a2 domain (M . McMillan, University
of Southern California, Medical Center, personal communication). Reactivities
were previously measured by cell-binding RIA of 1591 tumor cells or L cell
transfectants (12). 34-1-2 reactivities are unpublished data (H . Stauss). +, strong
reactivity ; ±, weak reactivity ; -, no reactivity .
BALB/c spleen cells . 5 d later, the cultures were tested for cytolytic activity against "Cr-
labeled target cells . CTL clones were generated as described previously (17) . All of the
clones are specific for H-2L' and were derived from either CBA anti-A.AL or (C3H X
dm2)F l anti-BALB/c cultures . The clones are maintained in the presence of rat Con A
supernatant and irradiated spleen feeder cells .
Target Cells.
￿
The target cells consisted of either L cells expressing transfected class I
genes or 1591 tumor cells . Targets were labeled with "Cr and between 2 X 10'-10' cells
were added to wells containing effector cells . After 4 h of incubation, the culture
supernatants were tested for radioactivity . Specific release = (experimental release -
spontaneous release)/maximum release .
CTL Competition Assay.
￿
This assay has been described previously (18) . Briefly, varying
numbers of unlabeled L or tumor cells were added to a mixture of effector and labeled
target cells in the cytolytic assay . Data are presented as : % inhibition = [ 1 - (specific
release in the absence of inhibitor cells - specific release in the presence of inhibitor
cells)/specific release in the absence of inhibitor cells] X 100 .
Expression of the Novel Antigens by L Cell Transfectants, and Serological Charac-
terization ofNovel Gene Products. The 1591 tumor is recognized by several allo-
and tumor-specific mAb unreactive with products expressed on normal C3H
tissues (9, 10) . As summarized in Table I, these include the syngeneic anti-1591
mAbs CP28 (9) and CP3F4 (9) and the H-2L crossreactive antibodies 34-1-2 (19,
20), 30-5-7 (19, 21), and 28-14-8 (19, 21) . Genomic X clones A149, A166, and
A216 were isolated from a 1591 genomic library on the basis of crosshybridiza-
tion to the class I-specific cDNA clone, pH-211a, and identified as encoding the
1591 tumor-specific epitopes by transfection into C3H L cellsand RIA screening
of transfectants with a panel of tumor-reactive antibodies, as previously described
(12) . The serological reactivities of the individual novel class I gene products, as
Cell line or
transfectant °` 1
34-I-2 34-4-20
oc
CP3F4
Antibodies
2
30-5-7 CP28
a3
28-14-8
1591 + - + + + +
A216 + - - - + -
A166 + - + + - +
A149 ± - - - - +
H-2Ld ± + - + - +
H-2Dd + + - - + -
H-21)d.1 + + - + - -
H-2K d + - + - - -149
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Sequencing strategy. Unique 2-3 kb restriction fragmentsof A216, A149, A166,
and X27.5 (represented by arrows) were subcloned into the polylinker of M13mp18 or mp19.
Subclonesof different genes could be distinguished by thepresence ofpolymorphic restriction
enzyme sites:B, Barn HI;P, Pst I; K, Kpn I; S, Sal 1; M, MboI; H, Hae 11; (not all sites shown).
Genes were sequenced in parallel using either the M13 universal primer or one of a set of
class I crosshybridizing primers synthesized according to the sequences of H-2D' (16) or H-
2K° (13) (P-40, C4243). Primers are numbered according to the H-2D' sequence. P primers
give sequence in the published orientation . C primers give complementary sequence. The
following primers were used: P-40, P249, P437, P493, P708, P989, P1210, P1509, P1810,
P1964, P2476, P2639, P2975, P3290, P3494, P3999, C286, C552, C580, C761, C1034,
C1240, C1540, C1803, C2000, C2222, C2400, C2727, C3066, C3226, C3390, C3580,
C3760, C3983, and C4243.
well as other related class I antigens, are summarized in Table I. All of the allo-
and tumor-specific class I serological reactivities seen on the 1591 tumor can be
accounted for by the reactivities of the three individual novel class I antigens.
We have described two of theseantigens as H-21--like becausethey are recognized
by at least two mAbs crossreactive with the H-2Ld antigen from BALB/c. A149,
A166, and H-2Ld share the determinants recognized by the mAbs 28-14-8 and
34-1-2 . In addition, both A166 and H-2Ld are recognized by the antibody 30-5-
7. The antibody 34-4-20 (22), on the other hand, recognizes neither H-2L-like
tumorantigen, although it recognizes both H-2Ld and H-2Dd. The A166-specific
mAb, CP3F4, crossreacts with H-2Kd, but it recognizes neither A149 nor H-2Ld
transfectants. The product of the A216 gene is identified by the anti-1591 mAb
CP28 . In addition, expression of the A216 and A149 products in BALB/c 3T3
cells indicates that these C31-derived antigens retain several H-2' haplotype
reactivities (data not shown).
DNA Sequence of the Novel Class I Genes Derived from the 1591 Tumor.
￿
The
nucleotide sequence of genes A149, A166, A216, and the H-2Ld clone X27.5
(14) were determined using the sequencing strategy described in Fig. 1. Briefly,
1-3-kb unique restriction fragments diagnostic for each of the X clones were
subcloned into the polylinker of M13mp18 or mp 19 . Templates derived from
these subclones were sequenced in parallel by the dideoxy-chain termination
method, using a set of 40 crosshybridizing synthetic oligonucleotides as primers
(see Fig. 1). Sequence differences between the genes could thus be confirmed
directly on the same gel.
The DNA sequences of the three novel class I genes are quite homologous to1798
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DNA Sequence of A149, A166, and H-2Ld . Unless otherwise specified, the
sequence of all three genes is identical . Coding regions are shown as triplets, translated amino
acid sequences are shown below . Numbering shown is for H-2Ld . Protein sequence numbering
begins at the first glycine in al domain . Deletions are represented by - . The Pst I sites
defining the 1-kb polymorphic Pst I fragment are underlined .
EAGN !-LEADER PEPTIDE
ATG GGG GCG ATG GCT CCG GGC ACC CTG C1'C GTG GIG CTG GCG GCC GCC CTC GCC CCG ACT CAG ACC CGC GCG G 73
Met Gly All Met All Pro Arg Thr Leu La, Lec Lc. . .ea All All All La. All Pro Thr Gln Thr Arg All G
INTRON 1
CTGACTGGGGTCGGGAGGGAAACGGCCTCTGCGGGGAGAGGGGCGGCACGGGGGAAGCCCGGTCCCCCGTCGCCCACCGGACCCTCCGCCCCTTCTCCAC 173
A16' T
CTGAGCCCCGCGCCCACATCCCCTCCCGGCCTGCGCAGCCGCCCGGGGTTTGGTCAGGAGGTCGGGGTCTCACCGCGCGCCGGCCCCAG 262
A106 T
EJ[ON 2-ALPHA! DOMAIN
GC CCA CAC TCG ATG CGG TAT TTC GAG ACC GCC GIG TCC CGG CCC GCC CTC GGG GAG CCC CGG TAG ATC TCT GTC GGC 339
ly Pro His Ser Met Arg Tyr Phe Glu Thr All Val Ser Arg Pro Gly Leu Gly Glu Pro Arg Tyr Ile Ser Val Gly 26
TAT GTG GAC AAC AAG GAG TTC GTG CGC TTC GAC AGC GAC GCG GAG AAT CCG AGA TAT GAG CCG CAC GCG CCG TOG ATG 417
Tyr Val Asp Ala Lye GI, Phe Val Arg Phe Asp Se, Asp Ala Glu As, Pro Arg Tyr Glu Pro Gln Ala Pro Trp Met 52
GAG CAC GAG GGG CCG GAG TAT TGG GAG CGG ATC ACG CAC ATC GCC AAG GGC CAG GAG CAG TGG TTC CGA GTG AAC CTG 495
Glu Gln
GI,
Gly Pro Glu Tyr Trp Glu Arg Ile Thr Gln Ile All Lye Gly Gln Glu Gln Trp Phe Arg Val As, La, 78
A166 A A T G
Asp As. Ser
A149 A
AGG ACC CTG CTC GGC TAC TAC AAC CAG AGC CCG GGC G 532
Arg Thr Lou Lee Gly Tyr Tyr As, Gln Set All GIy C 90
A168 GC G C
Ale Ale
INTRON 2
GTGAGTGACCCCGCGTCGGAGGTCAGGCCCCTCCACTTCCCGACACAGGGACGCTGACGTCCCGGGTCCCAAGTCCGAGGTTCGGGAACAGAACGGACCC 632
Alo6 G
GGAACCGGTTTCCCTTTCAGTTTGGACGAGTCCGCGGCCGGGCGGGCCGGGCCGGGGCGGGTGAGCGGGGCTGACCGCGGGGTCCCGCAG 722
A166 G
EXON 3-ALPRA2 DOMAIN
GC ACT CAC ACA CTC CAG TGG ATG TAC GGC TCT CAC GTG CGG TTC GAC GGG CGC CTC CTC CGC GGG TAC GAG CAG TTC 799
ly Thr His Thr Lou Gln Trp Met Tyr Gly Cye Asp Val Gly Sr Asp Gly Arg Lou Leu Arg Cly Tyr Glu Gln Phe 116
A16o T G A C T
So, Ile Arg Lou
A149 G A C T A
Ile Arg Trp Tyr
G CC TAC GAC CGC TGC GAT TAC ATC GCC CTG AAC GAA GAC CTG AAA ACG TGG ACG GCG GCG GAC ATG GCG GCG CAG ATC 877
Ale Tyr Asp Gly Cye Asp Tyr Ile All Lou As, Glu Asp La, Lye Thr Trp Thr All Ala Asp Met All All Ole Ile 142
A166 CT
La .
A149 A
ACC CIA CGC AAG MG GAG CAG GCT GGT GCT GCA GAG TAT TAG AM GCC TAO CTG GAG GGC GAG TGC GTG GAG TOG CTC 955
Thr Arg Arg Lys Trp Glu Gln Ala Gly All Ala Glu Tyr Tyr Arg Ala Tyr Lou Glu Gly Clu Cye Val Glu Trp La, 17E
Albe G C A
Gly Hl . Lye
A149 C A
His Lye
CAC AGA TAC CTC AAG AAC GGG AAC GCG ACC CTC CTG CGC ACA G 998
His Arg Tyr La, Lys Aen Gly Aen Ala Thr Lou Lou Arg Thr G 192
INTHON J
GTGCAGGGGCCGCGGGCAGCTCCTCCCTCTGCCCTCGGGCTGGGGCTCAGTCCTGGGGAAGAACAAACCCTCAGCTGGGGGTGATGCCCCTGTCTCAGAG 1098
A166 C C
GGGGAGAGAGTGACCCTGGGTCTCCTGATGCCTCAGCACAGTGACTGCACTGACTCTCCCAGGCTCAGCCTTCTCCCTGGACAGGGCCCAGCCTGTCTCA 1198
A166
GGAGGGAAGGAGAGAATTTCCCTGAGGTAACAACAGCTGCTCCCTTCAGTTCCCCTGTAGCCCTCTGTCAGCCATGGCCTCTCCCAGGCCGGGTTCTCTG 1296
CCCACGCCCACTGTCGGTGGACACTGACTCCTGTCCTGCTGAGTGTGTCAGCCCTTACACCTCAGGACCGGAAGTCGCCTTACCTGATTGGAAACATGGA 1398
CTCCTATACACTAGCCTGGTTGCCCCAGCTTCTAGAATTTTCCAGAGAATACATTCTCCCAGATCCCTCCCTGTCTGTGGGGTTTGCACCCCTTCGACAA 1496
A166 C
CCTAATTCTCTCTATTCCTACAGTGGTCAATGGTCACATGAGCTCTTATGGGGTACCCTGGAGGAATATAAATCGAGAATTTTCTTTTTTGTTTTCTCTC 1598
A166 --
A149 _-
TCTCTTTCTCTCTCTCTCTCTCTCTCTCTTTTCCGATTTTTTTCAGACACCGGGTCCCTCTGTATAGCCCTGGCTGTCCTGGAACTCACTTTGTAGCCCA 1698
A166 A
AAGGTGGTCCTCAAATTCACATGCCTCTGCCTCCTGAGTGCTGGGATTATGCACTGCCTGGGCCTTTCTTTTTTCTTTAC-------TTTTTTTTTTTTT 1791
A166 TTTTTTT
A149 _____--
TTTGAGGCCTTATTTTTTTTTTAGTCAGTTTTTGTCTGCACTGGAGTGATCCTGTTTCTCCATGCCCTTGTATTATCATTTGTATCAGTCTCCACAGGTG 1891
A166 C C
CCAGAGGAGACTCCTAACCTGGATAATTATGCAAGTTAAATCAGGGTTCTCATTAAAGCAGAGATTCTTCTGAACTTACAGTGTTTCCTGTCAGAACTAG 1991
A166 GA
ACATCCAGAAGCCTCCTCCTCTTCCTCTGCCCCCACAAGTTACAGTG--CCCCCCCCCCCAGTGAATCAGGACTTGCACTCTGAGAGACAGGGTCTTCTG 20a9
A166 CC
A149
CAATCCAGGGCTGGATTGAGAGGGAAGACCACACACCCTGTGACCTCACTGTGTTCCAGTGAGTGCTGCACTGGGGTCCACAGCTCACTCCAGGGATCCT 2189
GTTGTGACACACCTGTACCTTCTCCTCCAGAGTCAGGGGCAGGGAGTCATTTTCTCTGGCTACAGACTTTGTGATGGCTGTTCACTCGGACTCACAGTTA 2289
ACGTTGGTCAGCAAGATGACCACAATGGTTGAGTCTCAGTGGTGGGACCCTTCCAGTAGCATATGCCCCTAATTTTGATATGAACTCAAACAGATATTAA 2389
APTACTTATTTTCCATTCCCTATTCCATTCTGTGACTATCTCTCTCATGCTATTGAACATCACATAAGGATGGCCATCTTCACCCACTGGCTCATGTGGA 2489
TTCCCTCTTAGCTTCTTTGTCCCAAAAGAAAATGTCCAGTCCTGTGCTGAGGGGACCAGCTCTGCTTTTGGTCACTAGTGCAATGACAGTGTAGTGTCAA 2589
ATAGACACATAGTTCACTCTCATCATTGATTTAACTCAGTCTTGTGTAGATTTCAGTTTGTCTTGTTAATTGTGGAATTTCTTAAATCTTCCACACAG 2667
A166 CLINSK ET AL.
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those of other known class I genes (Figs. 2 and 3). Intron-exon boundaries of
A149 and A166 were assigned by comparison with the published sequences of
H-2Dd (16), H-2Ld (14), and H-2Db (23), and A216 by comparison with H-2Kk
(13). All three genes appear to comprise eight exons, the first encoding the
leader peptide; three exons encoding the three external domains, al, a2, and
a3; an exon encoding the hydrophobic transmembrane region; and three exons
accounting for the cytoplasmic domain of the antigen and the 3'-untranslated
trailer sequence . All splice junctions assigned for H-2Ld (14) and H-2Kk (13)
appear to be represented. Like H-2Ld, A149 and A166 each contain three
attachment sites for N-linked glycosylation ; like H-2Kk, A216 contains two. The
single amino acid substitution ofa leucine for a cysteine at residue 121 in the a2
of A 166, does not involve a cysteine normally involved in a disulfide bond.
Since the A216 gene encodes a product recognized by mAbs crossreactive
with H-2Kk, and since the A216-specific antibody CP28 crossreacts with H-2Dd,
we have compared the DNA sequence ofA216 with the published sequences of
these class I genes. The overall homology between A216 and H-2Dd is compa-
rableto that seen between other H-2 genes, such as H-2Ldor H-2Dd. Comparison
EAON 4-ALPHAS DOMAIN
AT TCC CCA AAG GCA CAT GTG ACC CAT CAC CCC AGA TCT AAA GOT GAA GTC ACC CTG AGO TOO TOO CCC CTG GGC TTC 2764
lu Se r Pro Lye Al. His Val Thr His His Pro Ara Ser Lye Gly Glu Val Thr Lou Ara Cys Trp Ala Leu Gly Phe 216
TAC CCT OCT GAG ATC AGO CTO ACC TOO CAG TTG AAT GGG GAG GAG CTO ACC CAG GAC ATG GAG CTT CTG GAG ACC AGO 2642
Tyr Pro Ale Asp Ile Thr Leu Thr Trp GIs Leu Aso Gly GI, Glu Lsu Thr Gla Asp Not Glu Leu Val GI, Tar Are 244
OCT GCA GGG GAT GCA ACC TTC CAG AAG TOO GCA TCT GTG GTG GTG CCT CTT GGG AAG GAG CAG AAT TAC ACA TGC COT 2920
Pro Ala Gly Asp Gly Thr Phe Gin Lye Trp Ala Bar Val Val Val Pro Lou Gly Lye Glu Gln Aso Tyr Thr Cys Ara 26O
GTC TAC CAT GAG GGG CTG COT GAO CCC CTC ACC CTG AGA TOG G 2963
Val Tyr His Glu Gly Leu Pro GI . Pro Lsu Thr Leu Ara Trp G 294
INTRON 4
GTAAGGAGGGTCTGGCTCCACAGCTGGGGTCAGGGAAAGCTGGAOCCTTCTGCAGACCCTGAGCTGGTCAGGCATGAGAGCTCGGGTCATAACCCTCACC 3081
TTCATTTCCTGTACCTGTCCTTCCCAC
EYON 5-TEANSMEMSRANE DOMAIM
AG CCT OCT CCG TOO ACT GAC TOT TAC ATG GTG ATC CTT OCT OTT CTC GOT OTC CTT GOA OCT ATG OCC ATC ATT GCA 3185
lu Pro Pro Pro Her Thr Asp Ser Tyr Mat Val Ile Val Ala Val Iwu Gly Val IAU Gly Ala Met Al. Ile Ile Gly 320
OCT GTO GTG OCT TTT GTG ATO AAG ACA AGO AGA AAC ACA G 3225
AIs Val Val Ala Phe VaI Met Lys Ara Ara Ara Aso Thr G 333
INTRON 5
GTAACAAACGGCAGGGTCTOAGTTTTCTCTOAGCCTCCTTTAGAAOTGTGCTCTCCTCATTAATGGGGAACACACCCACACCCCACATTGCTACTGTCTC 3325
TAACTGGGTCTGCTGTCAGTTCTGGGAATTTCCAGTGTCAAGATCTTCCTTGAACTCTCACAGCTTTTCTTTTCACAG 3403
EACH 6-CYTOPLASMIC DOMAIN
GT GGA AAA GOA GGO GAC TAT OCT CTG OCT CCA G 3436
ly Gly Lys Gly Gly Asp Tyr Ala Leu Ala Pro 0 344
INTHON 7
GTTAGTGTGGOGACAGGATGGTCTGGGOGACATTGOATTGAAGTTGGAGATGATGGGAOCTCTGGGAATCCATAATAGCTCCTCCAGAGAAATCTTCTAG 3536
GGGCCTGAGTTGTGCCATGAAGTGAATACATTCATGTACATATGCATATACATTTGTTTTOTTTTACCCTAG 3620
EIION 7- CYTOPLASNIC DOMAIN
GC TCC CAG AGC TCT GAA ATG TCT CTC CIA GAT TOT AAA G 3653
ly $er Gln Set Gar GI. Met Ser Lee Ara Asp Cya Lys A 367
uTRON e
GTCACACTCTAGGGTCTGATTGGGGAGGGGCAATGTGGACATGATTGGCTTTCAGGGACTCCCAGAATCTCCTGAGACTGAGTGGTGGGTTGCTGGAATG 3753
TTGTCTTCACAGTGATGGTTCATGACTCTCATTCTCTAG 3792
EAOM 8- TERMINATION CODON and 3' UNTRANSLATED REGION
CG TCA AGACAGCTGCCTGGACTGTACTGAGTGACAGACGATGTGTTCAGGTCTCTCCTCTGACATCCAGAGCCCTCAGTTCTCTTTACACAACATTC 3892
Is Tru 368
TCTGATOTTCCCTGTGACCTTGGGTTCAOTGTGAACAACTGTGGACCCCAGCCTGCCCTGCACACCAGGACCCTATCCCTGCACTGCCCTGTGTTCCCT 3992
TCCATAOCCAACCTTGCTGCTCCAGTCAAACACTGGGGGACATCTCCATCCTGTAAGCTCCATGCTACCCTGAG_CTGCAGCTCCTCACTTCCACACTGA 4092
A166 C
GAATAATAATTTGAATGTCCGTGGCTCGAGACATGGCTCAGCGCTGACTCCTCTTCCAAAGCTCCTGAGTTOAAATCCCAGCAACCACATGGTGGCTCA 4192800
￿
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EEON 1-LEADER PEPTIDE
ATC GCA C CG TOO ATG CTC CTC CTG CT .G TTG GIG CCC GCC CIO GCC CCG ACT CAC ACC CCC CCG G
￿
64
Met
Al,
Pro Cys Met Leu Leu Leu Lo . Lea Ale Ala Ala Leo Ala Pro Thr Gla Thr Arg Ale C
INTRON 1
GTGACTACCGCGCCGCCAGCGAAACCCCCTCTGACGCCACGGGCGCCATCGCCCAACCCGGTCCTCGGGTCGCCCACCGCACCCTCCGCCCCTTCTCCAT 164
CC CC OTC COCAGCCCCGACCCCTGCTCCCCTCTCAGCCCCCCCACCCGCCCCGGGTCTGGTGAGGAGCTCGCGCTCTCACCGCCCGCCCCCCCCAC
￿
260
EAON 2-ALPHA! DOMAIN
GC CCA CAT TCC CTC AGO TAT TIC OTC ACC GCC GTG TIC COG CCC GOT TTC GGG AAC CCC CCG TAC ATG GAA OTC GCC 337
ly Pro His Ser Lao Arg Tyr Phe Val Thr Ale Val Car Arg Pro Gly Phe Gly Lys Pro Are Tyr Met Glu Val Cly
￿
26
TAT GTG CAC GAC AGO GAG TIC GIG CGC TTC CAC AGC CAC GCG CAC AAT GIG AGA TAT GAG CIO COG GCG COG TOO ATA 415
Tyr Val Asp ASP Thr Clo Phe Val Arg Phe Asp Ser Asp Al, Glo As, Pro Arg Tyr Glo Pro Arg Ale Arg Trp Ile 52
GAG CAC GAG GGG C CG GAG TAT TOO GAG COG AAC ACA CAG AAC CCC AAC CGC ACT GAG CAC ACT TTC CGA GTC AAC CIO 493
G la Gln Cln Gly Pro Gla Tyr Trp Clo Arg As, Thr Gln As, Ale Lye Arg Ser Cl, Glo Ser Phe Arg Val As, Leo
￿
78
AGO ACC GCC CTC CGC TAG TAG AAC CAC ACC GCG GGC G
￿
530
Arg Thr Ale Leu Arg Tyr Tyr As, Clo Ser Al, Gly G
￿
91
INCHON 2
GTGACTGACCCCGGGTCGCAGGTCACCACCCCTCTACTTCCCGACAGCGACCTTGACCTCCCGGGTCCCAAGTCCGAGCTTCGGGAACACAACCGACCCG 630
CAGCCGGTTTCTCTTTCACTTTGGACGACTCCGCCGCCGGGCGGGCGGCGCCGGGGCCGGTGAGCGGGGCTCACCCCCTGCTCCCCAG
￿
71F
EFON 3-ALPHA2 DOMAIN
GC T CT CAC ACC ATC CAC CGG ATG TAT GGC TOT GAG GTG CCC TCG GAC ACC CGC CTC CTC CGC COG TAC GAG CAC TIC
￿
795
ly Ser His Thr Ile Gln Arg Met Tyr Cly Cys Glu Val Gly Ser Asp Arg Arg Leu Lea Arg Gly Tyr Gla Cl, Phe 116
G CC PAC CAC GGC TCC GAT TAG ATC GCC CTG AAC CAA GAC CTG AAA ACG TCG ACC GCC GCG GAC ATC CCG GCG CTG ATC 873
Ale Tyr Asp Gly Cys Asp Tyr Ile Ale Leo Asn Clu Asp Lao Lys Thr Trp Thr Ale Ala Asp Met Ala Ale Lea Ile 142
ACC "A CAC AAC TOO GAG GAG COT GOT CAA GCA GAG AGA TIC AGO GCC TAG CTA GAG CGC GTA TOO GTG GAG TCG CTC 951
Thr Lys His Lys Trp Glu Gln Cly Gly Glo Al . Gla Arg Phe Arg Ale Tyr Leu Cla Gly Val Cys Val Glu Trp Leu 168
AT TCC C CA AAG GCC CAT CTG ACC CAT CAC ACC AGA CCT G" CAT AAA GCC ACC CTG AGO TCC TOO CCC CTC CGC TIC 2820
sp Ser Pro Lye Ale His Val Thr His His Ser Arg Pro Gla Asp Lys Al . Thr Leu Arg Cya Trp Ale Lea Gly Phe 208
TAC CCT OCT GAC ATC ACC CTG ACC TOG CAC TIC AAT GOO GAG GAG CTC ACC CAG GAC ATC GAG CTT GIG GAG ACC AGG2698
Tyr Pro Al, Asp Ile Thr Lao Thr Trp Clo Lea As, Gly Gla Gla Leu Thr Gla Asp Met Cla Leu Val Olo Thr Arg 234
CC T G CA CGC GAT GGA ACC TIC CAG LAG TOO GCA TCT GTG GTG GTG CCT CTT GGG AAG GAG GAG TAT TAC ACA TCC CAT2976
Pro Als Gly Asp Gly Thr Phe Cln Lye Trp Ale Ser Val Val Val Pro Leu Cly Lys Cla Gln Tyr Tyr Thr Cys Hie 260
AC CCT CC T CCA TCC ACT CTC TCC AAC ACC CIA ATC ATT OCT OTT CIO CTT GTC CTT GCA OCT GCA ATA OTC ACT GGA 3222
la Pro Pro Pro Ser Thr Val Ser As, Thr Val Ile Ile Ala Val Leo Val Val Leu Gly Als Al. Ile Vel Thr Gly 30C
FIGURE 3.
￿
DNA sequence of the A216 gene. Coding sequences are shown as triplets with
the translated amino acid sequences below. Protein sequence numberingbegins at first glycine
in aI domain . The Pst I sites defining the 950-bp polymorphic Pst I fragment are underlined.
CTC AGA TAG CTG AAG AAC GGG AAC GCG ACC CTG CCG COG ACA G 994
Leu Arg Tyr Lao Lye As . Gly Aen Ale Thr Leu Val Arg Thr C 163
INTRON 3
GTGCACGGCCGCGGGCAGCTCCTCCCTCTGCCCTCGCGCTGGGGCTCAGTCCTGGGGAAGAAGAAACCCTCAGCTGGGCTGATGCCCCTGTCTCAGAGGG 1094
CAGACAGTGACCCTGGGTCTCCTGATCCCTCATCACAGGGACTGCACTGAGTCTCCCAGCCCTCAGCCTTCTCCCTGCACACTGCCCAGCCTGTCTCAGG 1194
0AAGGAGAGAATTT000TGAGGTAACAACAGCTCCTCCCTCTAGTTCCCCMCAGCCCTCTGTCAGCCATGGCCTCTCCCAGGCCGGGTTCTCTGCCCAT 1294
GCCCAGTGTCTCTCGACACTCACTCCTGTCCTGCTCAGTCTGTCAGCCCTTACACCTCAGGATCTGGAACTCTCCTTTCCTTCATTGGAGACATGGACTC 1394
CCCTACACTAGGACGGTTGACCTACCTTCTAGACTTTTCCMACAATACATTCTCACACATCCCTCCCTGTCTGTGGGCTTTTGCACCCCTT"CAACCC 1494
AGCTCTATCTATTCCTACAGTGGTGAATGCTCACATGACCCCTTATGGGCTACCCTGGAGGAATATAAATCCTGGATTTTCTTCTCTCTCTCTCTCTCTC 1594
TCTCTCTCTCTCTCTCTCTCTCTCTTTCCCTTTTTTTTTTTTCTTTTTCTTTTTTTTTTTCGTTTTGCTTTTTTTTTTTTTTTCCTAGACGGGCTTTCTC 1694
TCTATAGCCCTGGCTGTCCTGGAACTCACTTTGTAGACCAGCTTGGCCTTCAACTCAGAAATCTCCCTGCCTCTGGCTCCCGAGTGCTCGGATTA"GCA 1794
TCTGCCACCACTCCTGGCCTTTCTTTTTTCTTAACTTTTTTTTTTGGTGGGGGCGGGGGATGCTTATTTTCTTTCTACTCAGCTTTTGTCTGCATTCGAC 1894
TCATCCAGTCTCTCCATCCCCTCCTATTATCATTTGTTTCAGTCTCCACAGGTCCCACCGAACGCTCCTAACCTGGATAATTAGACAAGTTAAATCAGCC 1994
TTCGAATTAAAGAAGAGATTCTTGTGAACTTAGACTGTTTCCTGTCAGAACTAAACATGCAGAACCCTCCTGCTCTTCCTCTGCCCCACAACTTACAGTG 2094
CTCCCTCCCGCTAGTAAATCAGGACTTGGACTCTGAGAGGGCAGCGTCTTCTGCAATCCAGGGCTGAGTGAGAGGGAAGACCACACACCCTGTGAGCCCA 2194
CTGTGTTCCAGTGACTGCTGCACTCGCGTCCACACCACACTCCAGGCATCCTGTCTCACACACCTGTACCTTGTCCCCCAGAGTCAGGGGCTGGGACTCA 2294
I TTCTCTCGCTACACACTTACTGATGGCTCTTCACTTGGACTGACAGTTAATCTTGCTCAGC"GGTCACTACAATCCTTGAGTACCAACGGTGTCACC 2394
TTCCAGGATCATACACCCCTAATTTTAATATGAACTCAAACACATATTAAATTAGTTATTTTCCATTCCCTCCTCCATTCTTTGACTACCTCTCTCATGC 2494
TACCTCTCATCACATAAGGATCGCCATGTTTACCCACTGGCTCATCTGGATTCCCTCTTAGCTTCTGACTCCCAAAAGAAAATCTGCACTCCTGTGCTGA 2594
GGGCACCACCTCTGCTTTTGCTCACTAGTGCGATCACAGTTGAAGTGTCAAACAGACACATAGTTCACTCTCATCATTGATTTAACTCACTCTTGGCTAC 2694
ATTTCAGTTTCTCTTCTTAATTGTGTGATTTCITAAATCTTCCACACAC 2743
EAON 4-ALPRA3 DOMAIN
OCT GTG GIG OCT TTT GTG ATC AGO AGO AGO ACA AAC ACA C 3262
Als Val Val Ale Phe Val Met Arg Arg Arg Arg As, Thr G 314
INTRON 5
GTAGGAAACGGCAGCGTCTGAGTTTTCTCTCACCCTCCTTTACAGTCTGCTCTGCTCATCAATGGGGAACACACCCACACCCCACATTCCTACTGTCTOT 3362
AACTGGGTCTGCTCTCACTTCTCGG"CTTCCTACTCTCAAGATCTTCCTGCAACTCTCACACCTT^ .TCTTCTOACAG 3440
EEON 6-CYTOPLASMIC DOMAIN
GT GGA AAA GC A GCG GAC TAT OCT CTC OCT -CA 3 3573
ly Cly Lys Cly Gly Asp Tyr Ale Leo Al . Pro G 325
CTC TAC CAT CCA CCG CTG CCT CAC CCC CTC ACC CTG AGA TOO C 3019
Val Tyr His Lys Gly Lea Pro Glo Pro Leu Thr Leu Are Trp G 275
INTRON 4
GTAAGGAGGGTGTGGCTGCACACCTGGGCTCAGGGAAGCTGGAGCTTTCTGCAGACCCTCAGCTGCTCAGGGCTGACACCTGGGGTCATGACCCTCACCT 3119
TCATTTCTTGTACCTGTCCTTCCCAG 3145
EAON 5- TRANSMEMNRANE DOMAINLINSK ET AL.
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of A216 and the H-2K' from AKR revealed similar homology of 85-90%
throughout the 5' ends of these genes. Striking homology of >99%, however,
was seen between the 3' ends of these two genes, from a point ^-300 by 5' of
exon 4, and continuing for 1,800 by into 3'-untranslated sequences. A 1-kb
polymorphic Pst I restriction fragment not found in the C3H genome (12) maps
within this region, suggesting that the 3' end of this gene was generated by a
recombination event between two class I genes homologous to H-2Kk in this
region . Preliminary screening of the class I genes from a normal C3H library by
restriction mapping and with A216-specific oligonucleotide probes has identified
several potential 3' parents, including H-2Kk (S. Watts, University of California,
Berkeley, unpublished results) . Thus it is possible that H-2K'` is itself a parent,
and that the minimal degree of divergence, i.e., eight point differences and two
small clustered changes, seen between the 3' coding region ofA216 and the H-
2Kk sequence might reflectsequencing differences or strain substitutions between
the C3H and AKR H-2K alleles. Further sequence analysis of the normal C3H
genes will be required to unambiguously identify the parental genes.
Since the moleculesencodedby A 149 and A 166 share serological determinants
with each other and H-2Ld, we sequenced these genes in parallel. The complete
and revised sequence of H-2Ld, as well as the sequences ofthe two C3H-derived
H-2L-like genes, is presented in Fig. 2. The DNA sequences of the H-2L-like
tumor genes are nearly identical to each other, to H-2Ld, and to the correspond-
ing regions of an H-2Db cDNA clone (23) for 3,000 by from within the large
intron until the end ofthe 166 clone (Fig. 2). Within this region A149 is identical
to H-2Ld, and A166 exhibits only two bases that are polymorphic. The only
region of these genes for which <99.9% homology is found is within the exons
encoding the first and second external domains, al and a2, which are believed
to be the regions primarily responsible for T cell recognition (24). Within the
first 1,000 by of these genes, A149 and A166 are 99.1 and 98.6% homologous
to H-2Ld, respectively.
The two Pst I sites defining one of the polymorphic restriction fragments seen
in A149 and A166, but not in the C3H genome, map within the region of near
INTRON 6
GTTAGTGTGGCCACAGACTTGTCCTGGGGACATTGGAGTGAAGTTGGAGATGATCGGAGCTCTGGGAATCCATAATAGCTCCTCCAGAGAAATCTTCTA 3673
CCTGCCTGAGTTCTGCCATGAAATGAATATCTACATGTACATATGCATATACACTTGTTTTGTTTTACCCTAG 3746
EXON 7-CYTOPLASHIC DOMAIN
GC TCC CAC ACC TCT GAT CTC TCT CTC CCA GAT TGT AAA C 3785
ly
Gar
Cln Thr Sar Asp Leu Ser Leu Pro Asp Cys Lye G 338
INTRON 7
GTGACACTCTAGGCTCTGATTGGGGAGGGGCAATGTCGACATGATTGGGTTTCAGGAACTCCCAGAATCCCCTCTGAGTGACTGATGGGTTGTTCGAATG 3885
TTGTCTTCACAG 3897
EXON B-CYTOPLASMIC DOMAIN
TG ATC GTT CAT CAC CCT CAT TCT CTA GCG TGA 3929
al Met Val His Asp Pro His Ser Leu Ale Trm 347
3 ' - UNTRANSLATED REGION
AGACAGCTCCCTGGAGTGGACTTGGTGACAGACAATGTCTTCTCATATCTCCTCTGACATCCAGAGCCCTCAGTTCTCTTTAGTCAAGTGTCTGATGTTC 4029
CCTGTGAGCCTATGGACTCAATGTGAAGAACTGTGCAGCCCAGTCCACCCCTCCACACCAGGACCCTGTCCCTCCACTGCTCTCTCTTCCCTTCCACAGC 4129
CAACCTTGCTGGTTCAGCCAAACACTCAGGGACATCTGCAGCCTGTCAGCTCCATGCTACCCTCACCTGCAACTCCTCACTTCCACACTCAGAATAATAA 4229
TTTGAATGTAACCTTGATTGTTATCATCTTGACCTACGGCTCATTTCTTGTTAATTTCATGGATTGAGAATGCTTAGACCTTTTGTTTGTTTGTTTGATT 4329
CATTTGTTTTTTTGAAGAAATAAATGATAGATGAATAAACTTCCAGAATCTGGGTCACTATGCTCTGTGTATCTGTTCCGACAGGATGAAACTGTACCAC 4429
CTGAGTCTGAACAGGCTGTGCCGAGGTCGGCTCAGTCCCTTTTGATCTGTGATGGGGCCATACCTCCACTGTGTCACCTCTCGGCTCTGTTCCCTCTATC 4529
ACTATGAGGCACATGCTGAGAGTTTGTGGTCACAAAGACACAGGGAAGGCCTGAGCCTTTGCCTGTCCCCAGGATTATGAGCCCCCAGGGCTAAAGATCA 4629
GACACTCAGCCAGGGATCC 4662802
￿
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FIGURE 4.
￿
Comparison ofamino acid sequences of tumor antigens with other class I antigens .
Sequences are shown from the first and second external domains, al and a2 . Sequences
compared are A149, A166, A216, H-2Ld, H-2Dd (16), H-2Kd (25), H-2K° (13), and H-2Ddm'
(26) .
identity to H-2Ld at positions 3009 and 4047, suggesting that these H-2L coding
sequences exist in unexpressed form within the C3H MHC requiring a specific
recombination event to be activated . Since both A149 and A166 contain the
same polymorphic Pst I fragment, it is possible that they were generated by
duplication and divergence from a single parental recombinant gene . However,
analysis of 5'-flanking sequences and restriction enzyme site polymorphisms
indicate that these two genes are derived from different 5' parents (data not
shown) .
Structural Basis for Conserved Serological Determinants on Novel H-2L-like Anti-
gens . The data concerning the serological recognition of these novel gene
products can be analyzed in light of the predicted amino acid sequences (Figs .
2-4) . The identity between the three L-like antigens in the a3 domain, and the
extreme homology between the antigens in the a l domain are consistent with
the shared reactivities with 28-14-8 and 34-1-2, which have been shown to map
to the a3 and al domains, respectively (20, 21) . Since 34-1-2 binds A166 with
higher affinity than either A149 or H-2Ld (Table I), it is intriguing that three of
the five amino acid substitutions that A166 bears in the al domain with respect
to H-2Ld , render A166 more homologous to either H-2Kd (25) or H-2Dd , both
ofwhich are strongly reactive with 34-1-2 .
The lack of reactivity with the a2-specific antibody, 34-4-20 (M . McMillan,
University of Southern California, Los Angeles, CA ; personal communication),
seen for both tumor antigens, correlates with the presence of isoleucine and
arginine at positions 95 and 97 within a2 of both molecules. H-2Dd and H-2Ld ,
which are recognized by this antibody, both have leucine and tryptophan at these
two positions . The pattern of reactivity of the antibody, 30-5-7, appears more
complicated . Previously, exon-shuffling experiments (21), as well as analysis of
the 30-5-7 reactive H-2Dd,I molecule (26) mapped the epitope recognized byW H Q W J W K
U
U W a N
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FIGURE 5. Cytolytic T cell activity from tumor primed mice. (CM X dm2)F, mice were
primed with 1591 cells and their spleen cells were re-challenged with x-irradiated 1591 cells
(A) or BALB/c spleen cells (B). CTL generated were tested against 1591 cells (A), the 28-
tumor variant (p), or L cells transfected with A216 (p), A149 (Q), A166 (O), H-2L° (O), or
tk (0).
this antibody to the C-terminal two-thirds ofthe a2 domain. However, it is likely
that other regions will be involved in the formation of a functional antigenic
epitope, since A149, which is not 30-5-7-reactive, is quite conserved with H-2Ld
and A166, both of which are recognized. For example, the amino acid substitu-
tion of a tryptophan for a glycine at position 107 of A149 might somehow
interfere with the formation of a functional determinant by the rest of the
domain. Oligonucleotide-directed mutagenesis experiments should help resolve
this issue.
The tumor-specific mAb CP3F4 recognizes the antigens A166 and H-2K'.
Since the only amino acid residues unique to these molecules are a serine and an
alanine at positions 77 and 81 in the al domain, it is impossible to identify any
specific set of amino acids influencing the epitope recognized by this antibody
without additional mutagenesis experiments. Similarly, although the tumor-
specific antibody CP28 recognizes both A216 and H-2Dd (9), the available data
do not reveal any obvious pattern of unique structural homology between these
molecules.
Recognition ofNovel Antigens by Allospecific CTL.
￿
The 1591 tumor is highly
immunogenic and induces a strong CTL response when transplanted into normal
syngeneic mice (27, 28). To distinguish the components of the CTL response
directed against each of the novel class I antigens, we have tested L cells
transfected with the three individual genes for their ability to function as targets
for anti-1591 CTL. Since primary in vitro anti-1591 responses could not be
detected (data not shown), CTL populations directed against the tumor were
generated by immunization of (C3H X H-2dm2)F, mice with 107 1591 tumor
cells. 3 wk later the spleen cells of these mice were placed in culture with
irradiated 1591 stimulator cells. After a 5-d culture period, the effector cells
were tested against 5'Cr-labeled L cell targets, as well as 1591 and the 1591 (28-)
variant, selected in vitro for the loss ofthe three novel class I products (11). Both
1591 and L cells expressing each of the novel gene products were recognized
and effectively lysed by the anti-1591 CTL (Fig. 5a), as were BALB/c 3T3 cells80 4
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TABLE 11
Activity of Anti-H-2L° CTL Clones against 1591 Class 1 Molecules
CTL clones tested against panel of target cells listed above by specific chromium
release assay. E/T ratio, 20 .
transfected with the A216 gene (data not shown). L cells expressing the H2Ld
antigen were also recognized, but to a lesser extent . These data indicate that all
three novel class 1 products function as targets of the CTL generated against the
tumor. In addition, residual reactivity can be detected against the 28- tumor
variantlackingthesenovel antigens (reference 9, Fig. 5a). This residual reactivity
probably reflects the recognition of antigenic molecules distinct from the novel
class I products on this tumor. Wortzel et al. (28) have shown that 1591 expresses
at least four genetically distinguishable sets of novel tumor antigens, termed A,
B, C, and D, as defined by cloned CTL. Three of these antigens, B, C, and D,
remain on the 28- tumor variant (9), and are therefore not related to the novel
class I molecules discussed in this report . However, given that none of the tumor-
reactive mAbs block the anti-A CTL (29), it is not yet possible to determine the
relationship between any of the novel class I antigens and the A target molecule.
Since some anti-1591 CTL activity was directed towards H-2L' (27.5 cells)
(Fig. 5a); we cultured spleen cells from the 1591-immunized (CM X H-2d,2)F,
mice with BALB/c (H-2d) spleen cells. H-2d,2 is a meiotic mutant of BALB/c
that lacks the H-2Ld antigen. Therefore, this procedure should generate a
primary anti-H-2Ld response, as well as amplify any anti-H-2L' crossreactive
component that arose from the priming with 1591 cells. The effector cells
generated lysed 1591 tumor cells, L cells expressing the A149 antigen, and H-
2Ld (Fig. 5b). L cells expressing the A166 product were also killed, but much
less efficiently. In contrast to primed cells challenged in vitro with 1591 cells
(Fig. 5a), effector cells challenged in vitro with BALB/c spleen cells did not lyse
target cells expressing A216 or the 28- variant tumor line. This indicates that
the A216 antigen does not cross react with H-2Ld at the T cell level. It is likely
that the differential recognition of A149 and A166 by the anti-H-2L CTL
reflects some of the five amino acid differences that exist between the a1 domains
of these molecules.
To further study the relationships among H-2Ld, A149, and A166, we tested
bulk-cultured anti-H-2Ld CTL, as well as several anti-H-2Ld CTL clones, against
these target cells (Table 11). (C3H X dm2)FI anti-BALB/c (anti-H-2L) CTL
displayed lytic activity against H-2Ld and A149 transfectants, but not L cells
transfected with Al 66 or A216 (Fig. 6, left). Activity was also noted against the
Clone
Ltk Ld Dd A149
Target Cells
A166 A216 1591 28-
L9.4 0 19 6 5 ND 1 7 2
L9.24 2 31 2 5 1 2 0 1
L13 .D4 3 39 4 6 2 0 8 3
L13.D17 0 41 2 41 0 0 28 1
46(5)5.6 1 30 1 22 3 2 17 0
L11 .15 0 45 4 20 6 3 12 10
L13.D.8 0 18 3 23 ND 0 ND ND60
U
U
FIGURE 6.
￿
Anti-H-2Ld CTL activity vs. 1591 class I genes. (C3H x dm2)F, anti-BALB/c
CTL were tested against 1591 cells (0), 28- tumor variant (O), or L cells transfected with
A216 (C), A149 (O), A166 (1[1), H-2Ld (0), or tk (A). Data from left and right panels are from
two separate experiments.
1591 target cells (Fig. 6, right), but not the 28- variant. Four out of seven anti-
H-2Ld clones recognized A149 transfectants, while none lysed A166 transfectants
(Table II). Taken together with the data presented in Fig. 5b, these results
indicate that A149 extensively crossreacts with H-2Ld at the T cell level, while
A166 is much less crossreactive.
To further show that the A149 molecule, either expressed on the transfected
L cells or the 1591 tumor, crossreacts with allospecific anti-H-2Ld CTL, we
tested the ability of A149-expressing cells to block the cytolytic activity of an
anti-H-2Ld CTL clone, 1-1313.17. This clone lysed H-2Ld (27.5) and A149
transfectants, as well as 1591 cells (Fig. 7, a-c). The lysis of any of these three
targets could be blocked by adding an excess of 27.5, A149, or 1591 inhibitor
cells. No inhibition occurred when Ltk- or the 28- variant inhibitor cells were
added, as expected.
Thus, the above data show that the novel H-21--like antigens expressed on the
tumor can serve as targets for alloreactive anti-H-2Ld CTL. In addition, we
wished to determine whether these antigens could also function as restriction
elements for antigen-specific CTL. Therefore, we analyzed the reactivity of H-
2Ld-restricted anti-vesicular stomatitis virus (VSV)' CTL with VSV-infected L
cells expressing the class I molecules from the tumor. The H-21--like A149
antigen can, in fact, function as a restriction element for these H-2Ld-restricted
CTL (Fig. 8, a-c). No lytic activity against A216 or A166 transfectants was
shown (Fig. 8c). Thus the heirarchy of recognition of the tumor antigens by the
bulk and cloned anti-H-2Ld alloreactive CTL was comparable to that of the H-
2Ld-restricted CTL, suggesting perhaps that the same class I structures recog-
nized by allospecific CTL are involved in the function of class I restriction
elements.
' Abbreviation used in this paper:
￿
VSV, vesicular stomatitis virus.806
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FIGURE 7.
￿
Percent inhibition of lysis mediated by the anti-H-2L' CTL clone 1-13.1117 in the
presence of unlabeled competitor cells. L13.D17 was tested against "Cr-labeled L cells
transfected with H-2Ld (A), A149 (B), or 1591 cells (C). Unlabeled inhibitor cells are L cells
transfected with H-2L' (p), A149 (0), thymidine kinase (A), or 1591 tumor cells (o), or the
28- tumor variant (p). Specific release in the absence of inhibitor cells against H-2Ld L cells
(E/T, 10:1), A149 L cells (E/T, 10:1), and 1591 (E/T, 40:1) was 49, 33, 17, respectively.
FIGURE 8.
￿
Anti-VSV CTLactivity against 1591 class I antigens. Spleen cells from BDF, mice
that were primed with VSV were challenged in vitro with VSV-infected spleen cells. CTL that
were generated were tested against VSV-infected L cells transfected with H-2Ld (El), A149
(C), A166 (o), A216 (p), or tk (A). Data from three panels represent three separate
experiments.
Discussion
In addition to the normal complement of H-2Kk and H-211'`, the UV-induced
C3H (H-2k) fibrosarcoma, 1591, expresses at least three novel class I antigensLINSK ET AL.
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(12). Previous characterization of 1591 and 1591 tumor variants suggests that
these novel class I antigens might function as the primary targets of a CTL
response in normal histocompatible mice (9, 28). Since the loss of these products
correlates with the ability of certain variants of this normally nonmetastatic
tumor to escape immune rejection and progress to metastasis in immunocompe-
tent hosts (9, 11), it is clear that they play an essential role in limiting tumor
growth in the transplant situation. It is not obvious, however, what effect
expression of these products exerted on the progression of the tumor in its
original UV-irradiated host . While UV irradiation appears to induce a specific
suppression of the ability of normal mice to mount an immune response against
UV-induced tumors (5, 28), the immune elimination of other non-UV-induced
tumors remains relatively unimpaired (30, 31). Most UV-tumors express unique
tumor specific-antigens (9, 31), but the biochemical nature of these antigens and
their relationship, if any, to UV-specific suppression remain obscure. The 1591
fibrosarcoma is the first UV-induced tumor for which a molecular description of
any tumor antigens is available.
Before it is possible to define the specific immunobiological interactions that
the novel class I antigens might mediate when expressed on the developing
tumor, we believe that it is necessary to define the functional properties of these
molecules in the context of a competent immune system. It is also essential to
define the molecular origin of these antigens to determine whether their expres-
sion is, for example, a general response to the UV treatment.
To this end we have identified (12) the genes encoding the three novel class I
antigens expressed on the 1591 tumor, determined the DNA sequences of the
genes and the amino acid sequences of their predicted products, and character-
ized the functional recognition of these molecules on the 1591 tumor and on L
cells transfected with the individual novel tumor genes. The three novel class I
genes, A149, A166, and A216, encode polypeptides that are highly homologous
to, yet distinct from, previously characterized class I antigens. Since the 1591
tumor does indeed appear to be derived from C3H (9, 12), and the novel genes
account for several of the polymorphic restriction fragments observed in genomic
Southern blots comparing the class I genes of 1591 with those of normal C3H
tissue (12), these unique genes may have been generated by multiple recombi-
nation events among the endogenous class I genes of C3H.
In support of this hypothesis, the A216 antigen is extremely homologous to
the AKR H-2K' antigen throughout its C-terminal domain. The 5'-flanking
information encoded on the A clone containing this gene suggests strongly that
the 5' coding information of this gene is derived from the equivalent of one of
the cluster 8 genes defined from the BALB/c cosmid library (reference 32 and
S. Watts, University of California, Berkeley, unpublished results). The A216 X
clone not only contains a fragment of a second class I gene in a head-to-head
orientation, but hybridizes to a low copy probe specific for this cluster (31).
Furthermore, this clone contains a 7.7-kb polymorphic Hind III fragment
defined as representative of C3H (31), consistent with the C3H origin of this
gene. Although theH-2Kk gene may serve as a 3' parent, thecomplete description
of the events by which A216 was generated awaits further DNA sequence
comparison with the appropriate C3H loci.808
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One of the most intriguing features of this tumor is that 1591 expresses two
distinct, highly homologous, and immunologically crossreactive class I antigens .
A149 and A166 are>98% homologous to each other and to the H-2Ld antigen
from BALB/c . The genes encoding these three antigens are nearly identical for
2,000 by containing the exons encoding the third external domain, a3, the
transmembrane domain, and the cytoplasmic domain . Unique sequences within
the 5' ends of the genes account for the discrete functional differences observed
between their products . Since a polymorphic Pst I fragment not found in C3H
is contained within this region of near identity, it is possible thatA 149 andA166
were derived by duplication of a recombinant precursor gene, followed by
additional recombination events to generate the discrete differences between the
two tumor genes . Alternatively, the polymorphic 1.0-kb Pst I fragments found
in bothA 149andA166 might have been generated independently by comparable
recombination events involving two highly conserved parental genes. Additional
polymorphic restriction fragments map to the 5' end of the gene, suggesting
that multiple recombination events were required to generate each of these
novel genes (data not shown) . Identification and DNA sequence analysis of all of
the class I genes involved in these complex recombination events will probably
be necessary to define the precise recombinational pathway by which these novel
genes were generated .
The extensive sequence homologies observed amongA149, A166, and H-2L'
arealso shared with the 3' coding region ofthe H-2D b gene . Such unprecedented
sequence conservation between class I genes from three different haplotypes is
remarkable, and argues for an allelic relationship between these three sets of
genes (33) . In support of this hypothesis, a 5' flanking probe derived fromA 149
crosshybridizes to H-2Ld, and detects several class I genes from a normal C3H
library, which map to the Dend of the H-2 (e . g., H-2D'`) . Thus, although C3H
is not believed to express H-2L locus information, conserved H-2L coding
sequences may exist in an unexpressed configuration within the appropriate
region of the MHC.
The extreme structural conservation observed among A149, A166, and H-
2Ld is reflected by significant functional homology . The three antigens share
both public and private class I antigenic determinants, and most of the antigenic
differences that have been observed among these molecules appear to correlate
with discrete sequence substitutions . Previously, studies involving the serological
characterization of exon-shuffled class I gene products have succeeded in local-
izing the structures recognized by several different allospecific mAb to individual
protein domains (21, 34-37) . Unfortunately, attempts to correlate such serolog-
ical determinants with specific sets ofamino acids have been complicated by the
comparison of class I products that differ at multiple amino acid residues (38) .
However, given the ability of antibodies directed against discrete peptides to
recognize the native conformation of a protein (39), it is essential to determine
whether specific alloantibodies against H-2 react with conformational determi-
nants, or whether it is possible to identify specific coding sequences that can
function as independent epitopes .
While both A149 and A166 molecules are closely related to H-21Ld , both by
sequence and serological criteria, only the former molecule crossreacts exten-LINSK ET AL.
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sively with H-2L' at the T cell level. Thus, anti-1591 CTL react against H-2L',
A149, A166, and A216, while anti-H-2Ld CTL crossreact primarily with A149.
However, a distinct population of A166 crossreactive CTL could be shown by
challenging the spleen cells from tumor immune animals in vitro with H-21-d.
A149 and A166 differ from H-2Ld at 6 and 8 amino acid residues, respectively,
in the a2 domain. Four of the changes are shared by both A149 and A166, and
the additional unique changes found in A166 are no more different, with respect
to charge or side-chain bulk, than those seen in A149. In contrast, A166 has 5
amino acid changes in the al domain while A149 has none . Thus, these results
could indicate that the vast majority of anti-H-21-d CTL are controlled by
determinants mapping to the al domain. This is surprising, however, in light of
previous results that mapped some H-2Ld CTL determinants to the a2 domain.
Specifically, Murre et al. (37) have observed that a domain shuffled molecule
that contained the al of H-2Dd and the a2 of H-2L' retained anti-H-2Ld CTL
determinants . We (J . Forman, unpublished data) have noted that anti-H-2Ld
CTL also readily recognize the H-2d "' molecule, which has H-2Ld sequences
only in the carboxy-terminal end of the a2 domain, but H-2Dd sequences in the
a1 and the proximal half of the a2. Perhaps these observations can be reconciled
with the data discussed in this report by postulating that specific intramolecular
interactions with a1 structures are required to impart a recognizable conforma-
tion on a2-encoded determinants. Amino acid substitutions found in the a1 of
A166 might somehow interfere with these conformational interactions. Such
interactions might not be obvious from the analysis of the shuffled or dm l
molecules described above if the H-2Dd al domain was itself compatible with
the a2 of Ld. This hypothesis can be tested by generating mutant A166 molecules
in vitro, in which A166 residues are replaced with H-2Ld and Dd sequences.
Conformational interactions between class I domains have been implicated in
previous studies involving the H-2Kb series of class I mutants (40, 41) where one
to three amino acid changes in either the al or a2 domains usually result in the
loss of most of the CTL epitopes. Further evidence for conformational interac-
tions and the requirement for domain compatibilitycomes from studies involving
the shuffling of exons that encode the al and a2 domains of class I molecules
(34-36). In these studies it was found that virtually all of the CTL epitopes
characteristic of the native molecules are absent from the hybrid molecules.
Detailed study of the structural bases of these conformational interactions
might be uniquely accessible in the 1591/H-2Ld system for several reasons: (a)
the structural differences that exist between A149, A166, and H-2Ld are quite
discrete and can be easily manipulated by oligonucleotide directed mutagenesis;
(b) all three antigens seem able to evoke a CTL response; (c) A149 and A166
each crossreact to some extent with H-2Ld with respect to both CTL and
serological reagents; (d) discrete changes in crossreactivity will probably be
observed after in vitro mutagenesis; and (e) H-2Ld has already been extensively
characterized as a T cell target (17, 18, 35).
The crossreactivity of A 149 with H-2Ld was also noted with regard to antigen-
specific CTL. Thus, $DF, anti-VSV CTL, restricted to H-2Ld, also recognize
VSV antigens in association with A149 . These data indicate that the tumor not
only expresses a molecule that can function in the restriction of virus-specific81 0
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CTL, but also that the functional homology of A 149 to H-2Ld involves deter-
minants recognized by both allospecific and H-2-restricted CTL .
Taken together, our present results indicate that all three novel class I antigens
expressed on 1591 can function as potential target structures for the immune
destruction of the transplanted tumor in histocompatible hosts . Of course, the
immunogenicity of any one of these molecules could depend upon its relative
level of expression on the surface of the tumor cell, as well as the immunological
status and specific MHC background of the host . It is also difficult to predict the
precise effects of the expression of the two highly homologous, but distinct, H-
21--like antigens . Clearly, this tumor could progress in the autochthonous host
despite its extreme immunogenicity, and it is quite possible that the expression
of these novel antigens was somehow related to the UV-induced immune sup-
pression operative during tumor progression . Further immunobiological studies
involvingtumor variants and class I transfectants transplanted into UV-irradiated
and normal hosts may elucidate the precise effect each of these molecules might
mediate during tumor progression .
Summary
The UV-induced, C3H fibrosarcoma, 1591, expresses at least three unique
MHC class I antigens not found on normal C3H tissue . Here we report the
complete DNA sequence of the three novel class I genes encoding these mole-
cules, and describe in detail the recognition of the individual products by tumor-
reactive and allospecific CTL . Remarkably, although C3H does not appear to
express H-2L locus information, this C3H tumor expresses two distinct antigens,
termed A149 and A 166, which are extremely homologous to each other and to
the H-212 antigen from BALB/c . The gene encoding the third novel class I
antigen from 1591, A216, is quite homologous to H-2Kk throughout its 3' end .
Since all three of these genes account for polymorphic restriction fragments not
found in C3H, it is likely that they were derived by recombination from the
endogenous class I genes ofC3H . The DNA sequence homology ofA 149, Al 66,
and H-2Ld is especially significant given the functional conservation observed
between the products of these genes . Limited sequence substitutions appear to
correlate with some of the discrete serological differences observed between
these molecules . In addition, both A149 and A166 crossreact, but to differing
extents, with H-2Ld at the level of T cell recognition . Our results are consistent
with the view that CTL recognize complex conformational determinants on class
I molecules, but extend previous observations by comparing a set of antigens
with discrete and overlapping structural and functional differences .
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